Indication

Refractory Mediastinal Lymphoma

1 clinical trial

2 drugs

Clinical trial

A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients With Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)

Status: Active (not recruiting), Estimated PCD: 2025-06-30

Drug

Drug